FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1986898983> ?p ?o ?g. }

• W1986898983 endingPage "438" @default.
• W1986898983 startingPage "429" @default.
• W1986898983 abstract "The AZURE trial is an ongoing phase III, academic, multi-centre, randomised trial designed to evaluate the role of zoledronic acid (ZOL) in the adjuvant therapy of women with stage II/III breast cancer. Here, we report the safety and tolerability profile of ZOL in this setting. Eligible patients received (neo)adjuvant chemotherapy and/or endocrine therapy and were randomised to receive neither additional treatment nor intravenous ZOL 4 mg. ZOL was administered after each chemotherapy cycle to exploit potential sequence-dependent synergy. ZOL was continued for 60 months post-randomisation (six doses in the first 6 months, eight doses in the following 24 months and five doses in the final 30 months). Serious (SAE) and non-serious adverse event (AE) data generated during the first 36 months on study were analysed for the safety population. 3,360 patients were recruited to the AZURE trial. The safety population comprised 3,340 patients (ZOL 1,665; control 1,675). The addition of ZOL to standard treatment did not significantly impact on chemotherapy delivery. SAE were similar in both treatment arms. No significant safety differences were seen apart from the occurrence of osteonecrosis of the jaw (ONJ) in the ZOL group (11 confirmed cases; 0.7%; 95% confidence interval 0.3–1.1%). ZOL in the adjuvant setting is well tolerated, and can be safely administered in addition to adjuvant therapy including chemotherapy. The adverse events were consistent with the known safety profile of ZOL, with a low incidence of ONJ." @default.
• W1986898983 created "2016-06-24" @default.
• W1986898983 creator A5002979606 @default.
• W1986898983 creator A5003969811 @default.
• W1986898983 creator A5013820016 @default.
• W1986898983 creator A5014793113 @default.
• W1986898983 creator A5024501263 @default.
• W1986898983 creator A5032222537 @default.
• W1986898983 creator A5036008455 @default.
• W1986898983 creator A5036318976 @default.
• W1986898983 creator A5051980635 @default.
• W1986898983 creator A5052759268 @default.
• W1986898983 creator A5056951639 @default.
• W1986898983 creator A5069524701 @default.
• W1986898983 creator A5071164705 @default.
• W1986898983 creator A5079098518 @default.
• W1986898983 date "2011-03-11" @default.
• W1986898983 modified "2023-10-10" @default.
• W1986898983 title "Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer" @default.
• W1986898983 cites W1964424495 @default.
• W1986898983 cites W1968048788 @default.
• W1986898983 cites W1993035292 @default.
• W1986898983 cites W2008549280 @default.
• W1986898983 cites W2021852492 @default.
• W1986898983 cites W2026606540 @default.
• W1986898983 cites W2053335589 @default.
• W1986898983 cites W2054048948 @default.
• W1986898983 cites W2057064011 @default.
• W1986898983 cites W2060828257 @default.
• W1986898983 cites W2068522538 @default.
• W1986898983 cites W2069636127 @default.
• W1986898983 cites W2107208293 @default.
• W1986898983 cites W2112377187 @default.
• W1986898983 cites W2116883241 @default.
• W1986898983 cites W2121099142 @default.
• W1986898983 cites W2123367264 @default.
• W1986898983 cites W2125240512 @default.
• W1986898983 cites W2137302084 @default.
• W1986898983 cites W2147410460 @default.
• W1986898983 cites W2148096512 @default.
• W1986898983 cites W2148226416 @default.
• W1986898983 cites W2150904792 @default.
• W1986898983 cites W2153749576 @default.
• W1986898983 cites W2161226294 @default.
• W1986898983 cites W4229997548 @default.
• W1986898983 cites W4256653765 @default.
• W1986898983 doi "https://doi.org/10.1007/s10549-011-1429-y" @default.
• W1986898983 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21394500" @default.
• W1986898983 hasPublicationYear "2011" @default.
• W1986898983 type Work @default.
• W1986898983 sameAs 1986898983 @default.
• W1986898983 citedByCount "96" @default.
• W1986898983 countsByYear W19868989832012 @default.
• W1986898983 countsByYear W19868989832013 @default.
• W1986898983 countsByYear W19868989832014 @default.
• W1986898983 countsByYear W19868989832015 @default.
• W1986898983 countsByYear W19868989832016 @default.
• W1986898983 countsByYear W19868989832017 @default.
• W1986898983 countsByYear W19868989832018 @default.
• W1986898983 countsByYear W19868989832019 @default.
• W1986898983 countsByYear W19868989832020 @default.
• W1986898983 countsByYear W19868989832021 @default.
• W1986898983 countsByYear W19868989832022 @default.
• W1986898983 countsByYear W19868989832023 @default.
• W1986898983 crossrefType "journal-article" @default.
• W1986898983 hasAuthorship W1986898983A5002979606 @default.
• W1986898983 hasAuthorship W1986898983A5003969811 @default.
• W1986898983 hasAuthorship W1986898983A5013820016 @default.
• W1986898983 hasAuthorship W1986898983A5014793113 @default.
• W1986898983 hasAuthorship W1986898983A5024501263 @default.
• W1986898983 hasAuthorship W1986898983A5032222537 @default.
• W1986898983 hasAuthorship W1986898983A5036008455 @default.
• W1986898983 hasAuthorship W1986898983A5036318976 @default.
• W1986898983 hasAuthorship W1986898983A5051980635 @default.
• W1986898983 hasAuthorship W1986898983A5052759268 @default.
• W1986898983 hasAuthorship W1986898983A5056951639 @default.
• W1986898983 hasAuthorship W1986898983A5069524701 @default.
• W1986898983 hasAuthorship W1986898983A5071164705 @default.
• W1986898983 hasAuthorship W1986898983A5079098518 @default.
• W1986898983 hasBestOaLocation W19868989832 @default.
• W1986898983 hasConcept C120665830 @default.
• W1986898983 hasConcept C121332964 @default.
• W1986898983 hasConcept C121608353 @default.
• W1986898983 hasConcept C126322002 @default.
• W1986898983 hasConcept C141071460 @default.
• W1986898983 hasConcept C143998085 @default.
• W1986898983 hasConcept C197934379 @default.
• W1986898983 hasConcept C2776326535 @default.
• W1986898983 hasConcept C2776541429 @default.
• W1986898983 hasConcept C2776694085 @default.
• W1986898983 hasConcept C2777251235 @default.
• W1986898983 hasConcept C2777556957 @default.
• W1986898983 hasConcept C2777982462 @default.
• W1986898983 hasConcept C2778375690 @default.
• W1986898983 hasConcept C2908647359 @default.
• W1986898983 hasConcept C530470458 @default.
• W1986898983 hasConcept C61511704 @default.
• W1986898983 hasConcept C71924100 @default.

• next